

# Further development of a new model of generalised anxiety disorder: effects on processing of emotional material

<b>Submission date</b> 28/09/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 28/09/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 07/07/2017	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Marcus Munafo

### Contact details

C/O Research and Effectiveness Department  
Level 1, Old Building  
Bristol Royal Infirmary  
Marborough Street  
Bristol  
United Kingdom  
BS2 8HW  
+44 (0)117 928 3473  
R&E@ubht.nhs.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

N0264192826

# Study information

## Scientific Title

Further development of a new model of generalised anxiety disorder: effects on processing of emotional material

## Study objectives

This study will enable us to learn more about how the inhalation of carbon dioxide (CO<sub>2</sub>) produces anxiety. We can examine the psychological mechanisms of CO<sub>2</sub>-induced anxiety and see how these influence the processing of emotional material. These findings will aid our understanding of anxiety and validate the CO<sub>2</sub> model for use in studies of potential new treatments. It is widely accepted that anxiety results in altered processing of emotional material. Anxiety is also associated with physical symptoms such as racing heart, raised blood pressure, and muscle tension. We aim to examine the relationship between heart rate and blood pressure and altered processing of emotional material (i.e., are changes in the physical response to CO<sub>2</sub> related to changes in the psychological response?).

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Double-blind placebo-controlled randomised crossover study

## Primary study design

Interventional

## Secondary study design

Randomised cross over trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied

General anxiety disorder

## Interventions

Participants will complete a single test session, which will consist of the inhalation of air and the inhalation of 7.5% CO<sub>2</sub>, in counterbalanced order.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

Measures of processing of emotional information

**Secondary outcome measures**

Subjective measures of anxiety and cardiovascular function

**Overall study start date**

01/01/2007

**Completion date**

01/01/2008

**Eligibility****Key inclusion criteria**

1. Male and female participants
2. Aged 18-55
3. With a normal medical and psychiatric history, physical examination and ECG who give signed, fully-informed consent to participate

**Participant type(s)**

Healthy volunteer

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

55 Years

**Sex**

Both

**Target number of participants**

20

**Key exclusion criteria**

1. Females who are pregnant, breastfeeding, or not using adequate contraception
2. Presence of any pathological condition
3. Personal history of current or past psychiatric illness by psychiatric interview
4. Strong family history of mood disorder, including panic disorder
5. Personal history of cardiovascular or respiratory disease, including asthma
6. Personal history of migraine headaches requiring treatment
7. Cigarette smoking in the last 6 months
8. Drinking more than the recommended units of alcohol per week
9. Personal history of alcoholism or drug dependence
10. Drinking more than 8 caffeinated drinks per day
11. Medication use (except local treatment, or aspirin or paracetamol) within 8 weeks of testing
12. Potential, in the opinion of the investigator, to be non-compliant with study

**Date of first enrolment**

01/01/2007

**Date of final enrolment**

01/01/2008

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Bristol Royal Infirmary**

Bristol

United Kingdom

BS2 8HW

## **Sponsor information**

**Organisation**

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

**Sponsor details**

The Department of Health

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL  
+44 (0)20 7307 2622  
dhmail@doh.gsi.org.uk

**Sponsor type**  
Government

**Website**  
<http://www.dh.gov.uk/Home/fs/en>

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
United Bristol Healthcare NHS Trust

**Funder Name**  
NHS R&D Support Funding

## **Results and Publications**

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration